Triple Negative Breast Cancer & Aggressive Breast Cancer
Normal breast cells and some breast cancer cells have receptors that attach to the hormones estrogen & progesterone and the cancer cells depend on these hormones to grow. Breast cancer cells may have one, both or none of these receptors on their cell surface. The breast cancer cells also have another protein called Human Epidermal growth factor type 2 Receptor (HER-2 protein) on the cell surface. The presence of excess HER-2 protein on breast cancer cells is associated with more rapid cell growth.
The absence or presence of these receptors or proteins is detected using Immunohistochemistry analysis by the Histopathologist using a sample taken during your breast biopsy or after breast surgery.
- ER-Positive. Breast cancers with Oestrogen Receptors are called ER-positive (ER+)
- PR-Positive. Breast cancers with Progesterone Receptors are called PR-positive (PR+)
- Hormone receptor positive. If the cancer cells have one or both receptors, they may also be called Hormone receptor positive (HR+)
- Hormone receptor negative. If the cancer cells have neither of these receptors, they may also be called Hormone receptor negative (HR-)
- HER-2 Positive. If breast cancer cells demonstrate excess HER-2 protein, they are called HER-2+
Click to watch Roche video on TNBC
Around 10-20% of all breast cancers are Triple Negative Breast Cancer and more commonly seen in breast cancers of younger women.
Risk factors for TNBC include
- Never pregnant or given birth before
- Never having breast fed
- Women with BRAC gene mutation
- Being overweight with a high BMI
Triple Negative Breast Cancer means that your cancer tested NEGATIVE for the oestrogen receptor, progesterone receptor and excess HER-2 protein. It just means that your cancer is UNLIKELY to respond to Hormonal Therapy, but you can still go through the usual treatment for Breast Cancer. TNBC is usually more aggressive and has a higher risk of recurrence as well as distant cancer spread to other parts of the body.
Treatment Options for TNBC and other aggressive Breast Cancer types
TNBC is usually treated with a combination of surgery, radiation therapy and chemotherapy. The treatment plan may be modified by your doctors to consider of the more aggressive nature of your cancer.
- Neo-Adjuvant Chemotherapy. Your breast surgeon and oncologist may decide to start the chemotherapy before your surgery and radiation
- PARP Inhibitors. Poly ADP-Ribose Polymerase (PARP) inhibitors help to block aggressive cancer cells from being able to repair and survive. These medications include Olaparib (Lynparza) and Talazoparib (Talzenna)
- Immunotherapy. Immunotherapy drugs work by helping your immune system work smarter to attack cancer cells. These medications include Atezolizumab (Tecentriq) and Paclitaxel (Abraxane)
Disclaimer. TELEME blog posts contains general information about health conditions and treatments. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. The information is not advice and should not be treated as such.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?